Tsuda M, Kitazaki T, Ito T, Fujita T
Central Research Division, Takeda Chemical Industries, Ltd., Osaka, Japan.
J Bone Miner Res. 1986 Apr;1(2):207-11. doi: 10.1002/jbmr.5650010207.
The fetal long bone culture system developed by Raisz for the assessment of bone resorption was modified to improve the sensitivity, by using radii and ulnae separately, based on the observation of the consistently higher release of 45Ca from the radii than ulnae. Effects of ipriflavone (TC-80), an isoflavonoid derivative currently under clinical trial for its effect on osteoporosis, on bone resorption were examined in this new system. Ipriflavone and its metabolites (5 out of 6) at 10 micrograms/ml or more inhibited basal 45Ca release from bones. The inhibitory effects were still demonstrated in the presence of submaximal concentration of parathyroid hormone (12.5 ng/ml). The effect of ipriflavone on bone resorption was apparently not due to its toxicity on bone cells, since the inhibition was reversible.
赖兹开发的用于评估骨吸收的胎儿长骨培养系统进行了改良,以提高其敏感性。根据观察到桡骨释放的45Ca始终高于尺骨这一现象,分别使用桡骨和尺骨进行实验。在这个新系统中,研究了异黄酮衍生物依普黄酮(TC - 80)(目前正处于治疗骨质疏松症的临床试验阶段)对骨吸收的影响。依普黄酮及其代谢产物(6种中的5种)浓度在10微克/毫升及以上时,可抑制骨骼基础45Ca的释放。在甲状旁腺激素亚最大浓度(12.5纳克/毫升)存在的情况下,这种抑制作用仍然存在。依普黄酮对骨吸收的作用显然不是由于其对骨细胞的毒性,因为这种抑制作用是可逆的。